Structure and Origin of Uterine and Extragenital L=Ibroids Induced
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
A Guide to Feminizing Hormones – Estrogen
1 | Feminizing Hormones A Guide to Feminizing Hormones Hormone therapy is an option that can help transgender and gender-diverse people feel more comfortable in their bodies. Like other medical treatments, there are benefits and risks. Knowing what to expect will help us work together to maximize the benefits and minimize the risks. What are hormones? Hormones are chemical messengers that tell the body’s cells how to function, when to grow, when to divide, and when to die. They regulate many functions, including growth, sex drive, hunger, thirst, digestion, metabolism, fat burning & storage, blood sugar, cholesterol levels, and reproduction. What are sex hormones? Sex hormones regulate the development of sex characteristics, including the sex organs such as genitals and ovaries/testicles. Sex hormones also affect the secondary sex characteristics that typically develop at puberty, like facial and body hair, bone growth, breast growth, and voice changes. There are three categories of sex hormones in the body: • Androgens: testosterone, dehydroepiandrosterone (DHEA), dihydrotestosterone (DHT) • Estrogens: estradiol, estriol, estrone • Progestin: progesterone Generally, “males” tend to have higher androgen levels, and “females” tend to have higher levels of estrogens and progestogens. What is hormone therapy? Hormone therapy is taking medicine to change the levels of sex hormones in your body. Changing these levels will affect your hair growth, voice pitch, fat distribution, muscle mass, and other features associated with sex and gender. Feminizing hormone therapy can help make the body look and feel less “masculine” and more “feminine" — making your body more closely match your identity. What medicines are involved? There are different kinds of medicines used to change the levels of sex hormones in your body. -
Estradiol-17Β Pharmacokinetics and Histological Assessment Of
animals Article Estradiol-17β Pharmacokinetics and Histological Assessment of the Ovaries and Uterine Horns following Intramuscular Administration of Estradiol Cypionate in Feral Cats Timothy H. Hyndman 1,* , Kelly L. Algar 1, Andrew P. Woodward 2, Flaminia Coiacetto 1 , Jordan O. Hampton 1,2 , Donald Nickels 3, Neil Hamilton 4, Anne Barnes 1 and David Algar 4 1 School of Veterinary Medicine, Murdoch University, Murdoch 6150, Australia; [email protected] (K.L.A.); [email protected] (F.C.); [email protected] (J.O.H.); [email protected] (A.B.) 2 Faculty of Veterinary and Agricultural Sciences, University of Melbourne, Melbourne 3030, Australia; [email protected] 3 Lancelin Veterinary Hospital, Lancelin 6044, Australia; [email protected] 4 Department of Biodiversity, Conservation and Attractions, Locked Bag 104, Bentley Delivery Centre 6983, Australia; [email protected] (N.H.); [email protected] (D.A.) * Correspondence: [email protected] Received: 7 September 2020; Accepted: 17 September 2020; Published: 21 September 2020 Simple Summary: Feral cats (Felis catus) have a devastating impact on Australian native fauna. Several programs exist to control their numbers through lethal removal, using tools such as baiting with toxins. Adult male cats are especially difficult to control. We hypothesized that one way to capture these male cats is to lure them using female cats. As female cats are seasonal breeders, a method is needed to artificially induce reproductive (estrous) behavior so that they could be used for this purpose year-round (i.e., regardless of season). -
The Reactivity of Human and Equine Estrogen Quinones Towards Purine Nucleosides
S S symmetry Article The Reactivity of Human and Equine Estrogen Quinones towards Purine Nucleosides Zsolt Benedek †, Peter Girnt † and Julianna Olah * Department of Inorganic and Analytical Chemistry, Budapest University of Technology and Economics, Szent Gellért tér 4, H-1111 Budapest, Hungary; [email protected] (Z.B.); [email protected] (P.G.) * Correspondence: [email protected] † These authors contributed equally to this work. Abstract: Conjugated estrogen medicines, which are produced from the urine of pregnant mares for the purpose of menopausal hormone replacement therapy (HRT), contain the sulfate conjugates of estrone, equilin, and equilenin in varying proportions. The latter three steroid sex hormones are highly similar in molecular structure as they only differ in the degree of unsaturation of the sterane ring “B”: the cyclohexene ring in estrone (which is naturally present in both humans and horses) is replaced by more symmetrical cyclohexadiene and benzene rings in the horse-specific (“equine”) hormones equilin and equilenin, respectively. Though the structure of ring “B” has only moderate influence on the estrogenic activity desired in HRT, it might still significantly affect the reactivity in potential carcinogenic pathways. In the present theoretical study, we focus on the interaction of estrogen orthoquinones, formed upon metabolic oxidation of estrogens in breast cells with purine nucleosides. This multistep process results in a purine base loss in the DNA chain (depurination) and the formation of a “depurinating adduct” from the quinone and the base. The point mutations induced in this manner are suggested to manifest in breast cancer development in the long run. -
Steroid Sex Hormones Non Steroid Hormones Fig. A1. Chemical
Electronic Supplementary Material (ESI) for Analytical Methods. This journal is © The Royal Society of Chemistry 2015 Steroid sex hormones O OH H H H H H H O Testosterone (T) HO Estrone (E1) OH O H H H H H H O HO 17β-Estradiol (17β-E2) 4-Androstene-3,17-dione (AND) OH OH H OH H H H H H H O HO Nandrolone (NAN) Estriol (E3) OH OH H H H H H H O 17α-Methyltestosterone (17α-MT) HO Ethinylestradiol (EE2) OH O O H HO OH H H H H H H O Prednisolone (PRED) O Progesterone (P) Non steroid hormones HO CH3 HO CH3 H C OH H C OH 3 Diethylstilbestrol (DES) 3 Hexestrol (HEX) Fig. A1. Chemical structure of selected endocrine disruptors. Fig. A2. Scheme of SPE procedure: a) PTFE disks, b) nylon filter membrane. Table A1. Characterization data for mesoporous silicas a Material BET surface Pore volume Pore L0C18 Particle morphology Average particle size 2 -1 3 -1 -1 (m g ) (cm g ) diameter (Å) (mmol C18 g ) (length x wide) SBA-15-C18 796 0.88 76 0.69 Cylindrical 1.4 µm x 750 nm a Amount of octadecyl groups per gram of silica Q3 Q4 Q2 DH 50 0 -50 -100 -150 -200 (ppm) 29 Fig. A3. Si NMR spectrum of SBA-15-C18. 140 0 % Weight Loss T 120 -5 100 s s o L Exothermic Procces 80 t -10 ) h C º g i 60 ( e T W Endothermic Procces -15 % 40 20 -20 0 -25 -20 100 200 300 400 500 600 700 800 T (ºC) Fig. -
New Pharmacological Treatments for Equine Reproductive Management
New Pharmacological Treatments for Equine Reproductive Management P. J. Burns, Ph.D.11,2,3,4, D. L. Thompson, Jr, Ph.D.5, W. A. Storer Ph.D.5 R. Gilley B.S1,2,3., C. Morrow, D.V.M.3, J. Abraham, B. S. 7 & R. H. Douglas, Ph.D. 1,2,3 1BioRelease Technologies LLC, Birmingham, AL 2BET Pharm, Lexington, KY 3 Mt Laurel Veterinary Pharmacy, Birmingham, 4Burns BioSolutions INC, Lexington, KY 5Animal Sciences Department, Louisiana State University, Baton Rouge, LA 6 Mobile Veterinary Practice, Amarillo, Tx, 7 Abraham Equine, Mendota Ranch, Canadian,Tx Introduction Loy (1970) reported that only 55% of mares bred annually produce live foals. Recent data from The Jockey Club (2006) indicate that only 37,025 of 64,123 (57.7%) of thoroughbred mares bred during 2005 produced live foals. This is considerably lower than foaling rates of 71 to 85%, which are reported on farms where extensive reproductive management is used. Overall, reproductive management has not improved much in the last 30 years. The long estrus period, with ovulation at any time from 1 to 10 days after the beginning of estrus, has made reproductive management of cyclic mares time-consuming, expensive and most importantly, inefficient. Furthermore, the confusion associated with the long and variable transition from anestrous to cyclicity in mares greatly magnifies the complexity of efficient reproductive management for this category of mares. There is a need to develop and capitalize on controlled breeding programs for the horse industry based on new advances in the understanding of cost effective hormonal control of reproduction in mares and stallions. -
Pp375-430-Annex 1.Qxd
ANNEX 1 CHEMICAL AND PHYSICAL DATA ON COMPOUNDS USED IN COMBINED ESTROGEN–PROGESTOGEN CONTRACEPTIVES AND HORMONAL MENOPAUSAL THERAPY Annex 1 describes the chemical and physical data, technical products, trends in produc- tion by region and uses of estrogens and progestogens in combined estrogen–progestogen contraceptives and hormonal menopausal therapy. Estrogens and progestogens are listed separately in alphabetical order. Trade names for these compounds alone and in combination are given in Annexes 2–4. Sales are listed according to the regions designated by WHO. These are: Africa: Algeria, Angola, Benin, Botswana, Burkina Faso, Burundi, Cameroon, Cape Verde, Central African Republic, Chad, Comoros, Congo, Côte d'Ivoire, Democratic Republic of the Congo, Equatorial Guinea, Eritrea, Ethiopia, Gabon, Gambia, Ghana, Guinea, Guinea-Bissau, Kenya, Lesotho, Liberia, Madagascar, Malawi, Mali, Mauritania, Mauritius, Mozambique, Namibia, Niger, Nigeria, Rwanda, Sao Tome and Principe, Senegal, Seychelles, Sierra Leone, South Africa, Swaziland, Togo, Uganda, United Republic of Tanzania, Zambia and Zimbabwe America (North): Canada, Central America (Antigua and Barbuda, Bahamas, Barbados, Belize, Costa Rica, Cuba, Dominica, El Salvador, Grenada, Guatemala, Haiti, Honduras, Jamaica, Mexico, Nicaragua, Panama, Puerto Rico, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Suriname, Trinidad and Tobago), United States of America America (South): Argentina, Bolivia, Brazil, Chile, Colombia, Dominican Republic, Ecuador, Guyana, Paraguay, -
Estrogen-Induced Endogenous DNA Adduction
Proc. Natl. Acad. Sci. USA Vol. 83, pp. 5301-5305, July 1986 Medical Sciences Estrogen-induced endogenous DNA adduction: Possible mechanism of hormonal cancer (estradiol/synthetic estrogens/renal carcinoma/Syrian hamster/32P-labeling analysis) J. G. LIEHR*, T. A. AVITTSt, E. RANDERATHt, AND K. RANDERATHtt *Department of Pharmacology, University of Texas Medical Branch, Galveston, TX 77550; and tDepartment of Pharmacology, Baylor College of Medicine, Houston, TX 77030 Communicated by Paul C. Zamecnik, March 24, 1986 ABSTRACT In animals and humans, estrogens are able to but the mechanism of this effect has not been elucidated. In induce cancer in susceptible target organs, but the mecha- view ofthe extensive use ofcompounds with estrogenic activity nism(s) of estrogen-induced carcinogenesis has not been eluci- in human medicine (20, 21) and in agriculture (22) and the dated. A well-known animal model is the development of renal occurrence of estrogenic compounds as contaminants in food carcinoma in estrogen-treated Syrian hamsters. Previous work (22, 23), it is important to define how these compounds cause demonstrated the presence of covalent DNA addition products cancer. (adducts) in premalignant kidneys of hamsters exposed to the A central question to be addressed in this context is whether synthetic estrogen, diethylstilbestrol, a known human carcin- or not estrogens, like the majority of chemical carcinogens, ogen. In the present study, the natural hormone, 178-estradiol, induce covalent DNA alterations in the target tissue of and several synthetic steroid and stilbene estrogens were exam- carcinogenesis in vivo. In the present study, experiments were ined by a 32P-postlabeling assay for their capacity to cause carried out to search for adduct formation in an established covalent DNA alterations in hamster kidney. -
Gender-Affirming Hormone Therapy
GENDER-AFFIRMING HORMONE THERAPY Julie Thompson, PA-C Medical Director of Trans Health, Fenway Health March 2020 fenwayhealth.org GOALS AND OBJECTIVES 1. Review process of initiating hormone therapy through the informed consent model 2. Provide an overview of masculinizing and feminizing hormone therapy 3. Review realistic expectations and benefits of hormone therapy vs their associated risks 4. Discuss recommendations for monitoring fenwayhealth.org PROTOCOLS AND STANDARDS OF CARE fenwayhealth.org WPATH STANDARDS OF CARE, 2011 The criteria for hormone therapy are as follows: 1. Well-documented, persistent (at least 6mo) gender dysphoria 2. Capacity to make a fully informed decision and to consent for treatment 3. Age of majority in a given country 4. If significant medical or mental health concerns are present, they must be reasonably well controlled fenwayhealth.org INFORMED CONSENT MODEL ▪ Requires healthcare provider to ▪ Effectively communicate benefits, risks and alternatives of treatment to patient ▪ Assess that the patient is able to understand and consent to the treatment ▪ Informed consent model does not preclude mental health care! ▪ Recognizes that prescribing decision ultimately rests with clinical judgment of provider working together with the patient ▪ Recognizes patient autonomy and empowers self-agency ▪ Decreases barriers to medically necessary care fenwayhealth.org INITIAL VISITS ▪ Review history of gender experience and patient’s goals ▪ Document prior hormone use ▪ Assess appropriateness for gender affirming medical -
Progesterone and Estradiol Benzoate. (Iii) Limitations
Food and Drug Administration, HHS § 522.1940 0.28 milligrams of isopropamide) in (ii) Indications for use. For increased buffered aqueous solution. rate of weight gain. (b) Sponsor. See No. 000069 in (iii) Limitations. For use in suckling § 510.600(c) of this chapter. beef calves (at least 45 days of age) up (c) Conditions of use. (1) The drug is to 400 pounds (lb) of body weight. For used in dogs and cats in which gastro- subcutaneous ear implantation, one intestinal disturbances are associated dose per animal. Do not use in bull with emotional stress. calves intended for reproduction. Safe- (2) Dosage is administered by sub- ty and effectiveness have not been es- cutaneous injection twice daily as fol- tablished in veal calves. A withdrawal lows: period has not been established for this product in preruminating calves. Do Dosage in Weight of animal in pounds Milliliters not use in calves to be processed for veal. Up to 4 ................................................................. 0.25 (2) Steers—(i) Amount—(A) 200 mg pro- 5 to 14 ................................................................. 0.5–1 15 to 30 ............................................................... 2–3 gesterone and 20 mg estradiol benzoate 30 to 45 ............................................................... 3–4 (one implant consisting of 8 pellets, 45 to 60 ............................................................... 4–5 each pellet containing 25 mg progester- Over 60 ................................................................ 6 one and 2.5 mg estradiol benzoate) per implant dose. Following the last injection, admin- (B) 200 mg progesterone and 20 mg es- ister prochlorperazine and tradiol benzoate (one implant con- isopropamide sustained release cap- sisting of 9 pellets, each of 8 pellets sules as indicated. containing 25 mg progesterone and 2.5 (3) For use only by or on the order of mg estradiol benzoate, and 1 pellet con- a licensed veterinarian. -
Profiles of Circulating Estradiol-17Β After Different Estrogen Treatments in Lactating Dairy Cows
Anim. Reprod., v.2, n.4, p.224-232, Oct./Dec. 2005 Profiles of circulating estradiol-17β after different estrogen treatments in lactating dairy cows A.H. Souza1, A.P. Cunha1, D.Z. Caraviello1, M.C. Wiltbank1,2 1Department of Dairy Science, 1675 Observatory Drive, University of Wisconsin, Madison, WI, USA 53706 Abstract Washburn et al., 2002). One of the physiological aspects that may affect reproductive efficiency in The objective of this study was to characterize lactating dairy cows is the elevated metabolism of the circulating concentrations of estradiol-17β (E-17β) estradiol-17β (E-17β; Sangsritavong et al., 2002). This after treatment with different types or doses of estrogens high E-17β metabolism appears to be due to the in the absence (Experiment 1) or presence (Experiment 2) elevated liver blood flow that is coincident with of a dominant follicle in lactating cows. In Experiment 1, elevated dry matter intake in lactating dairy cows cows (n = 12) had all follicles > 5 mm removed by (Sangsritavong et al., 2002). High rates of E-17β ultrasound-guided follicular aspiration every 12 h metabolism result in reduced circulating E-17β throughout the blood sampling period. Estrogen concentrations in lactating cows compared to non- treatments started 48 h after the first follicular aspiration. lactating cows (Sartori et al., 2002a; 2004) and in Treatments were: no treatment, E-17β (0.5 mg), or lactating cows with high milk production compared to estradiol benzoate (EB, 0.5 mg). Seven days after the cows with low production (Lopez et al., 2004; 2005). end of the first trial, cows were then re-randomized to Since E-17β is involved in many aspects of reproductive receive: no treatment, E-17β (1.0 mg), EB (1.0 mg), or physiology, this reduction in circulating E-17β could estradiol cypionate (ECP, 1.0 mg). -
Hormone Replacement Therapy and Osteoporosis
This report may be used, in whole or in part, as the basis for development of clinical practice guidelines and other quality enhancement tools, or a basis for reimbursement and coverage policies. AHRQ or U.S. Department of Health and Human Services endorsement of such derivative products may not be stated or implied. AHRQ is the lead Federal agency charged with supporting research designed to improve the quality of health care, reduce its cost, address patient safety and medical errors, and broaden access to essential services. AHRQ sponsors and conducts research that provides evidence-based information on health care outcomes; quality; and cost, use, and access. The information helps health care decisionmakers— patients and clinicians, health system leaders, and policymakers—make more informed decisions and improve the quality of health care services. Systematic Evidence Review Number 12 Hormone Replacement Therapy and Osteoporosis Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 2101 East Jefferson Street Rockville, MD 20852 http://www.ahrq.gov Contract No. 290-97-0018 Task Order No. 2 Technical Support of the U.S. Preventive Services Task Force Prepared by: Oregon Health Sciences University Evidence-based Practice Center, Portland, Oregon Heidi D. Nelson, MD, MPH August 2002 Preface The Agency for Healthcare Research and Quality (AHRQ) sponsors the development of Systematic Evidence Reviews (SERs) through its Evidence-based Practice Program. With guidance from the third U.S. Preventive Services Task Force∗ (USPSTF) and input from Federal partners and primary care specialty societies, two Evidence-based Practice Centers—one at the Oregon Health Sciences University and the other at Research Triangle Institute-University of North Carolina—systematically review the evidence of the effectiveness of a wide range of clinical preventive services, including screening, counseling, immunizations, and chemoprevention, in the primary care setting. -
(12) United States Patent (10) Patent No.: US 8,022,053 B2 Mueller Et Al
US008022053B2 (12) United States Patent (10) Patent No.: US 8,022,053 B2 Mueller et al. (45) Date of Patent: Sep. 20, 2011 (54) ORAL SOLID DOSAGE FORMS CONTAINING 4,755,386 A 7, 1988 Hsiao et al. A LOW DOSE OF ESTRADIOL 5,073,374. A 12/1991 McCarty 5,776.492. A 7/1998 Betzing et al. 5,891,867 A * 4/1999 Lanquetin et al. ............ 514,170 (75) Inventors: Kristina Mueller, Berlin (DE); Torsten 5,891,868 A 4/1999 Cummings et al. Wagner, Berlin (DE); Adrian Funke, 6,030,988 A 2/2000 Gilis et al. Berlin (DE); Christian Zurth, Berlin 6,060,077 A * 5/2000 Meignant ...................... 424/434 (DE) 6,323,366 B1 1 1/2001 Wolfe et al. 6,326,366 B1* 12/2001 Potter et al. ................... 514, 182 6,455,069 B1 9, 2002 Michaud et al. (73) Assignee: Bayer Schering Pharma 6,521,253 B1 2/2003 Forsman et al. Aktiengesellschaft, Berlin (DE) 6,558,707 B1 5/2003 Thosar et al. 6,653,298 B2 * 1 1/2003 Potter et al. ................... 514, 182 (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 (Continued) U.S.C. 154(b) by 1017 days. FOREIGN PATENT DOCUMENTS (21) Appl. No.: 11/262,952 EP 04.078O140 11, 2004 (Continued) (22) Filed: Nov. 1, 2005 OTHER PUBLICATIONS (65) Prior Publication Data The Contraception Report, “Bioecuivalence between Brand-Name US 2006/O 111334 A1 May 25, 2006 and Generic OCs.” Jun. 2002, 13(2), 6-8.* Related U.S.